House full session on novel methods to target kinases by Dr. Nathanael Gray from Dana Farber #CovalentInhibitors #PROTACS #CancerResearch
Identification of covalent inhibitors that disrupt M. tuberculosis growth by targeting multiple serine hydrolases involved in lipid metabolism
#openscience #drugdiscovery #covalentinhibitors
A great review on recent progress in chemistry for selective covalent targeting of proteins and their applications in targeted covalent inhibitor designs
cutt.ly/kWjC49O
#drugdiscovery #openscience #covalentinhibitors #protein
Design your novel #CovalentInhibitors with our original #Fragments & #BuildingBlocks bearing activated double bonds.
Details 👉bit.ly/LC-Covalent_in…
Please request the full collection at 📧 [email protected] or order compounds online 🛒shop.lifechemicals.com
Next up in our Applications of #MolecularSimulations session we have Dr Ajay Abisheck Paul George (Ajay A. Paul George) from BioSolveIT , discussing Embracing the resurgence of #covalentinhibitors from a #moleculardocking perspective
#compchem #ozchem #CADD
Happy for sharing our most recent (open access) review paper! Universität Tübingen
Check it out!
Ps: my first as corresponding author 😊
doi.org/10.1016/j.crch…
#ChemicalProbes
#MedicinalChemistry
#ChemicalBiology
#DrugDesign
#DrugDiscovery
#CovalentInhibitors
#CovalentWarheads
Working with Covalent Inhibitors? Don't miss the opportunity to publish in our SI from Pharmaceuticals MDPI (IF 5.863)! It's open for submission! More details:
mdpi.com/journal/pharma…
Chiara Borsari
#ChemicalProbes
#MedChem
#ChemicalBiology
#drugdiscovery
#CovalentInhibitors
It's finally out! Huge congrats to Ayah & @Yasir_Raouf for their 10-year comprehensive review of #covalent #kinaseinhibitors in Chem Soc Rev!! A must-read if you're interested in targeting kinases with #covalent inhibitors. #drugdiscovery #medicinalchemistry pubs.rsc.org/en/content/art…
Check out the #Janpix poster today at #AACR20 (Abstract LB-108) to see preclinical data for the JPX platform of monovalent #STAT3 and #STAT5 degraders in #AML and #TPLL ! #targetedproteindegradation #covalentinhibitors #hematologicmalignancies
abstractsonline.com/pp8/#!/9045/pr…
Our report of #CovalentInhibitors for HIV reverse transcriptase: pnas.org/content/early/… Includes 10 crystal structures
Interested in #covalent inhibitors ? Did you know that the 3-bromo-4,5-dihydroisoxazole warhead has a drug-like reactivity? Check out our recent paper, Glad to have been part of this amazing work! #MedChem #covalent #GAPDH #pancreaticcancer
sciencedirect.com/science/articl…
#20 From the first author's bday-This week's best read from Stephan Hacker group ensures proteome wide profiling of D,E in living bacteria by 2,5 disub tetrazoles. #covalentinhibitors #drugtargets #importantsites #aureus #Npt #GuaA #FabH #inivovsinvitro
pubs.acs.org/doi/10.1021/ac…
If you are interested in #covalentinhibitors targeting lysine, check: Covalent and noncovalent strategies for targeting Lys102 in HIV-1 reve... sciencedirect.com/science/articl…
Advantages of using IC50(t) over kinact/Ki in covalent inhibitor optimization from my colleague Atli Thorarensen #PFEcolleague #covalentinhibitors lnkd.in/ehsTk5q
Covalent Warheads Reloaded: Emerging and Re-emerging Covalent Warheads Application in MedChem/Chemical Biology. Check it out in the new JMC paper from the Gehringer group #MedChem #DrugDiscovery
#CovalentInhibitors
#ChemicalProbes
#ChemicalBiology
pubs.acs.org/doi/10.1021/ac…
A new technology that combines covalent inhibitors and PROTACs has emerged—covalent PROTAC technology, including reversible covalent and irreversible covalent PROTACs.
us.huatengsci.com/news/show/1649…
#CovalentPROTACs #CovalentInhibitors #ReversibleCovalent #IrreversibleCovalent
📢 #SpecialIssue 'Targeted #CovalentInhibitors in #DrugDiscovery , Chemical Biology and Beyond' Deadline Extended
👏Guest Editors: Prof. Dr. Matthias Gehringer, Dr. Chiara Borsari and Dr. Ricardo Augusto Massarico Serafim
⏰New Deadline: 20 March 2023
👉mdpi.com/journal/pharma…
Mickael Mogemark talks about coalent inhibitors from a safety perspective and shares the safety parameters they use at AstraZeneca when designing these. #EFMC_ACSMEDI2019 #MedChem #Pharma #DrugDiscovery #CovalentInhibitors #DrugDesign
#Structuralbiology used to gain insight into the mechanism of action of #covalentinhibitors of the #deubiquitinase UCHL1 (Flaherty Lab Purdue Borch MCMP Mayo Clinic Purdue Chemistry @DiscoveryParkPU) doi.wiley.com/10.1002/cbic.2…
